Hengrui Pharma has received the clinical trial approval notice for the drug Ruvelimab tablets
I'm PortAI, I can summarize articles.
Hengrui Pharma recently received approval from the National Medical Products Administration to begin clinical trials of Relugolix tablets, in combination with injectable HS-20093 for prostate cancer. Relugolix tablets are a second-generation AR inhibitor, which has a stronger inhibitory effect compared to the first generation and has no agonistic effect. The drug was approved for market launch in 2022 and is suitable for patients with high tumor burden metastatic hormone-sensitive prostate cancer
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments